Biotectix Announces Issue of Key U.S. Patent
Ann Arbor, Michigan - Biotectix, LLC announced today the issuance of U.S. Patent # 8,005,526 entitled “Biologically Integrated Electrode Devices.” Biotectix is the exclusive licensee of this intellectual property from the University of Michigan. Bioelectrodes having enhanced features are disclosed in the patent along with methods of making and using the devices. The invention facilitates transmission of electrical signals by creating an intimate connection between an electrode such as an implantable cardiac or neuromodulation device and living tissue.
Dr. James Arps, General Manager at Biotectix, noted that “this patent is an important component in our strategy to establish Biotectix as the world leader in the development and use of proprietary conductive polymers, enabling the creation of high performance implantable electrodes for stimulation and sensing. When combined with IP acquired from Chameleon BioSurfaces earlier this year, we have established a comprehensive IP position which will benefit our co-development and licensing partners in the medical device industry.
Inventors on the ‘526 patent include Drs. David Martin, Sarah Richardson Burns, and Jeffrey Hendricks, all of whom are Biotectix founders originally associated with the University of Michigan. Additional related pending applications and continuations in part from the University are exclusively licensed by Biotectix and are expected to provide solid coverage encompassing all essential elements of the company’s technology offerings.
About Biotectix Biotectix is developing a new class of conductive polymer materials and coatings for implantable devices and sensors that improve the safety, longevity, reliability, biological integration, and function of implantable biomedical devices. A number of benefits are driven by this platform technology without changing device size, shape, or implant procedure, including improved electrical performance, biocompatibility, and tissue response. The technology addresses key limitations faced by the medical device industry including foreign body reactions, component stability, and long-term electrical performance in vivo. The materials are custom-designed for the specialized mechanical, electrical, and biological environments of the body, and provide an extremely high level of functional interfacing for medical electrodes. Biotectix was formed by Allied Minds, a private equity company, based on technology originally developed at the University of Michigan, Ann Arbor. The founders and inventors continue to develop and validate the technology through research, collaborations, and partnerships with leading companies and research institutions. For more information please visit www.biotectix.com.
About Allied Minds Allied Minds is a private equity-funded innovation company that forms, funds, manages and builds startups based on early-stage technology developed at renowned U.S. universities and national labs. We serve as a diversified holding company that supports our businesses with capital, management and shared services. Allied Minds is the premier firm to utilize this novel and fully-integrated approach to technology commercialization. Our investments span multiple business sectors and offer an attractive risk-return profile, a deliverable timeline and groundbreaking products and services. Our subsidiaries include BA Logix, Biotectix, Cephalogics, CryoXtract, Illumasonix, ProGDerm, Precision Biopsy, Purtein, RF Biocidics, SaltCheck, SciFluor Life Sciences, SiEnergy Systems, SoundCure and Spin Transfer Technologies. We don't just fund the startup. We are the startup. www.alliedminds.com.
For more information:
James Arps
Vice President & General Manager
Biotectix, an Allied Minds Company
734-585-5126
jim.arps@biotectix.com
